Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8th, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
加利福尼亞州弗裏蒙特，2024年4月29日（GLOBE NEWSWIRE）——領先的細胞分析解決方案公司Cytek Biosciences, Inc.（納斯達克股票代碼：CTKB）今天宣佈，將在5月8日星期三收盤後公佈2024年第一季度的財務業績第四，2024。該公司的管理層將從太平洋時間下午 1:30 /美國東部時間下午 4:30 開始網絡直播相應的電話會議，討論其業績、業務發展和前景。
Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com.
網絡直播的直播音頻將在公司網站的 “投資者” 欄目上提供，網址爲 投資者.cytekbio.com。
About Cytek Biosciences, Inc.
關於 Cytek Biosciences, Inc
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek Biosciences（納斯達克股票代碼：CTKB）是一家領先的細胞分析解決方案公司，通過利用其專利的全光譜分析（FSP）技術提供高分辨率、高內容和高靈敏度的細胞分析，推動下一代細胞分析工具的發展。Cytek的新方法利用熒光信號整個光譜中的信息力量，以精度和靈敏度實現更高水平的多路傳輸。Cytek 的 FSP 平台包括其核心儀器 Cytek Aurora 和北極光系統；其細胞分選器 Cytek Aurora CS；Cytek Orion 試劑混合物製備系統；Amnis 下的流式細胞儀和成像產品 和番石榴 品牌；以及試劑、軟件和服務，爲其客戶提供全面和集成的解決方案套件。Cytek 總部位於加利福尼亞州弗裏蒙特，在全球設有辦事處和分銷渠道。有關該公司及其產品的更多信息，請訪問 cytekbio.com。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的產品僅用於研究用途，不用於診斷程序（Cytek的Northern Lights-CLC系統和某些試劑除外，它們在中國和歐盟可供臨床使用）。
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek、全譜分析、FSP、Cytek Aurora、北極光、Cytek Orion、Amnis 和 Guava 是 Cytek Biosciences, Inc. 的商標。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向美國證券交易委員會（SEC）提交文件、新聞稿、公開電話會議和網絡直播外，Cytek還使用其網站（cytekbio.com）， 領英頁面 和 X（前身爲 Twitter）賬號 作爲發佈有關其公司、產品、計劃中的財務和其他公告、出席即將舉行的投資者和行業會議以及其他事項的信息的渠道。此類信息可能被視爲重要信息，Cytek可以使用這些渠道來履行其在FD法規下的披露義務。因此，投資者除了關注其向美國證券交易委員會提交的文件、新聞稿、公開電話會議和網絡直播外，還應監控Cytek的網站、LinkedIn頁面和X賬戶。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒體聯繫人：
斯蒂芬妮·奧爾森
拉格斯與同事
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
pgoodson@cytekbio.com
投資者聯繫人：
保羅·古德森
投資者關係主管
pgoodson@cytekbio.com
譯文內容由第三人軟體翻譯。